Literature DB >> 8234339

Transforming growth factor beta 1 (TGF-beta 1) controls expression of major histocompatibility genes in the postnatal mouse: aberrant histocompatibility antigen expression in the pathogenesis of the TGF-beta 1 null mouse phenotype.

A G Geiser1, J J Letterio, A B Kulkarni, S Karlsson, A B Roberts, M B Sporn.   

Abstract

The phenotype of the transforming growth factor beta 1 (TGF-beta 1) null mouse has been previously described and is characterized by inflammatory infiltrates in multiple organs leading to a wasting syndrome and death as early as 3 weeks after birth. Since this phenotype occurs in the absence of any detectable pathogen, potential autoimmune disease mechanisms were investigated. We examined major histocompatibility complex (MHC) mRNA expression in tissues of the TGF-beta 1 null mouse and found levels of both the class I and class II MHC mRNA elevated compared to normal or TGF-beta 1 heterozygous littermates. This elevated expression was seen prior to any evidence of inflammatory infiltrates, suggesting a causal relationship between increased MHC expression and activation of immune cell populations. Cell surface expression of MHC molecules was detected by immunohistochemistry and correlated well with mRNA levels. Expression of mRNA for interferon gamma and its receptor was unchanged at the ages when increased MHC expression became apparent. Down-regulation of class I MHC expression by TGF-beta 1 was also demonstrated in vitro in fibroblasts isolated from TGF-beta 1 null mice. These findings suggest that one natural function of TGF-beta 1 is to control expression of both MHC classes. Altered regulation of MHC expression may be a critical step leading to the multifocal inflammation and wasting syndrome seen in the TGF-beta 1 null mouse. These results suggest potential applications for TGF-beta in the management of autoimmune disease, allograft rejection, and other problems associated with altered MHC expression.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8234339      PMCID: PMC47689          DOI: 10.1073/pnas.90.21.9944

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  49 in total

Review 1.  MHC molecules and beta-cell destruction. Immune and nonimmune mechanisms.

Authors:  L C Harrison; I L Campbell; J Allison; J F Miller
Journal:  Diabetes       Date:  1989-07       Impact factor: 9.461

Review 2.  Inappropriate major histocompatibility complex class II expression by thyroid follicular cells in thyroid autoimmune disease and by pancreatic beta cells in type I diabetes.

Authors:  R Pujol-Borrell; I Todd; M Londei; A Foulis; M Feldmann; G F Bottazzo
Journal:  Mol Biol Med       Date:  1986-04

3.  Regulation of cell adhesion receptors by transforming growth factor-beta. Regulation of vitronectin receptor and LFA-1.

Authors:  R A Ignotz; J Heino; J Massagué
Journal:  J Biol Chem       Date:  1989-01-05       Impact factor: 5.157

4.  Structure of the human class I histocompatibility antigen, HLA-A2.

Authors:  P J Bjorkman; M A Saper; B Samraoui; W S Bennett; J L Strominger; D C Wiley
Journal:  Nature       Date:  1987 Oct 8-14       Impact factor: 49.962

5.  Molecular characterization of the murine interferon gamma receptor cDNA.

Authors:  C S Kumar; G Muthukumaran; L J Frost; M Noe; Y H Ahn; T M Mariano; S Pestka
Journal:  J Biol Chem       Date:  1989-10-25       Impact factor: 5.157

6.  In vivo administration with IL-1 accelerates the development of collagen-induced arthritis in mice.

Authors:  J T Hom; A M Bendele; D G Carlson
Journal:  J Immunol       Date:  1988-08-01       Impact factor: 5.422

7.  Endothelial adhesiveness for blood neutrophils is inhibited by transforming growth factor-beta.

Authors:  J R Gamble; M A Vadas
Journal:  Science       Date:  1988-10-07       Impact factor: 47.728

8.  Transforming growth factor-beta 1 modulates the expression of class II histocompatibility antigens on human cells.

Authors:  C W Czarniecki; H H Chiu; G H Wong; S M McCabe; M A Palladino
Journal:  J Immunol       Date:  1988-06-15       Impact factor: 5.422

9.  Cell adhesion protein receptors as targets for transforming growth factor-beta action.

Authors:  R A Ignotz; J Massagué
Journal:  Cell       Date:  1987-10-23       Impact factor: 41.582

10.  Cytokines in synovial fluid: II. The presence of tumour necrosis factor and interferon.

Authors:  S J Hopkins; A Meager
Journal:  Clin Exp Immunol       Date:  1988-07       Impact factor: 4.330

View more
  38 in total

1.  A combination of a transforming growth factor-beta antagonist and an inhibitor of cyclooxygenase is an effective treatment for murine pulmonary tuberculosis.

Authors:  R Hernández-Pando; H Orozco-Esteves; H A Maldonado; D Aguilar-León; M M Vilchis-Landeros; D A Mata-Espinosa; V Mendoza; F López-Casillas
Journal:  Clin Exp Immunol       Date:  2006-05       Impact factor: 4.330

2.  A mechanism of suppression of TGF-beta/SMAD signaling by NF-kappa B/RelA.

Authors:  M Bitzer; G von Gersdorff; D Liang; A Dominguez-Rosales; A A Beg; M Rojkind; E P Böttinger
Journal:  Genes Dev       Date:  2000-01-15       Impact factor: 11.361

3.  Ecsit is required for Bmp signaling and mesoderm formation during mouse embryogenesis.

Authors:  Changchun Xiao; Jae-hyuck Shim; Michael Klüppel; Samuel Shao-Min Zhang; Chen Dong; Richard A Flavell; Xin-Yuan Fu; Jeffrey L Wrana; Brigid L M Hogan; Sankar Ghosh
Journal:  Genes Dev       Date:  2003-11-21       Impact factor: 11.361

4.  Autoimmunity associated with TGF-beta1-deficiency in mice is dependent on MHC class II antigen expression.

Authors:  J J Letterio; A G Geiser; A B Kulkarni; H Dang; L Kong; T Nakabayashi; C L Mackall; R E Gress; A B Roberts
Journal:  J Clin Invest       Date:  1996-11-01       Impact factor: 14.808

Review 5.  Connection between inflammation and carcinogenesis in gastrointestinal tract: focus on TGF-beta signaling.

Authors:  Suntaek Hong; Ho-Jae Lee; Seong Jin Kim; Ki-Baik Hahm
Journal:  World J Gastroenterol       Date:  2010-05-07       Impact factor: 5.742

6.  Loss of TGF-beta signaling contributes to autoimmune pancreatitis.

Authors:  K B Hahm; Y H Im; C Lee; W T Parks; Y J Bang; J E Green; S J Kim
Journal:  J Clin Invest       Date:  2000-04       Impact factor: 14.808

7.  End-organ damage in a mouse model of fulminant liver inflammation requires CD4+ T cell production of IFN-gamma but is independent of Fas.

Authors:  Richard T Robinson; Jing Wang; James G Cripps; Michael W Milks; Kathryn A English; Todd A Pearson; James D Gorham
Journal:  J Immunol       Date:  2009-03-01       Impact factor: 5.422

Review 8.  Transforming growth factor beta (TGF-beta) and inflammation in cancer.

Authors:  Brian Bierie; Harold L Moses
Journal:  Cytokine Growth Factor Rev       Date:  2009-12-16       Impact factor: 7.638

9.  Synthetic fibronectin peptides interrupt inflammatory cell infiltration in transforming growth factor beta 1 knockout mice.

Authors:  K L Hines; A B Kulkarni; J B McCarthy; H Tian; J M Ward; M Christ; N L McCartney-Francis; L T Furcht; S Karlsson; S M Wahl
Journal:  Proc Natl Acad Sci U S A       Date:  1994-05-24       Impact factor: 11.205

10.  Regulation of tumor immune surveillance and tumor immune subversion by tgf-Beta.

Authors:  Hae-Young Park; Lalage M Wakefield; Mizuko Mamura
Journal:  Immune Netw       Date:  2009-08-31       Impact factor: 6.303

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.